A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer

This is a single-center, prospective, two cohort study to evaluate the efficacy and safety of surufatinib in combination with AG or AG alone in the first-line treatment of patients with locally advanced or metastatic pancreatic cancer. Participants with previously received AG chemotherapy for 2 cycles with no disease progression will be enrolled: Arm 1: Surufatinib plus AG chemotherapy (q3w) until disease progression/death/withdrawn; Arm 2: AG chemotherapy (q3w) until disease progression/death/withdrawn; During the treatment period, imaging methods were used to evaluate the tumor status eve

Trial Details

NCT ID
NCT05969171
Phase
PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Surufatinib, gemcitabine, nab-paclitaxel
  • Nab-paclitaxel, gemcitabine
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Subjects must meet all of the following criteria for enrollment:
  • The subjects voluntarily joined the study and signed the informed consent with good compliance and follow-up;
  • Unresectable, locally advanced or metastatic pancreatic cancer confirmed by histopathology or cytology;
  • Aged between 18 and 75 (including 18 and 75), male or female;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →